New combo drug trial aims to stall advanced breast cancer
NCT ID NCT05963984
Summary
This study tested whether adding an experimental drug called samuraciclib to the standard hormone therapy fulvestrant could better control advanced breast cancer that has stopped responding to prior treatments. It involved 60 adults with hormone receptor-positive, HER2-negative breast cancer that had spread or was locally advanced. Participants were randomly assigned to receive either the combination or fulvestrant alone to compare safety and how well the cancer was controlled.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Actualidad Basada en la Investigación del Cáncer
Guadalajara, Jalisco, 44280, Mexico
-
Centro de Investigacion Clinica de Oaxaca
Oaxaca City, 68020, Mexico
-
Cryptex Investigación Clínica S.A. de C.V.
Cuauhtémoc, 06100, Mexico
-
Dr. Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve Arastırma Hastanesi
Ankara, 06200, Turkey (Türkiye)
-
Gazi University
Ankara, 06120, Turkey (Türkiye)
-
Gulhane Egitim ve Arastirma Hastanesi
Ankara, 06010, Turkey (Türkiye)
-
Hacettepe Universite Hastaneleri
Ankara, 06230, Turkey (Türkiye)
-
Hospital Clinico San Carlos
Madrid, Madrid, Comunidad de, 28040, Spain
-
Hospital Clinico de Valencia
Valencia, 46010, Spain
-
Hospital Infanta Cristina
Badajoz, 06080, Spain
-
Hospital Universitari Vall d'Hebron
Barcelona, 08035, Spain
-
Hospital Universitario Marqués de Valdecilla
Santander, Cantabria Comunidad de, 39002, Spain
-
Hospital Universitario de Salamanca - Complejo Asistencial Universitario de Salamanca
Salamanca, 37007, Spain
-
Hospital Vithas Málaga
Málaga, 29016, Spain
-
I.E.U. Medical Point Hastanesi
Izmir, 35575, Turkey (Türkiye)
-
Institut Català d'Oncologia - L'Hospitalet
L'Hospitalet de Llobregat, Barcelona, 08908, Spain
-
Istanbul Universitesi Istanbul Tıp Fakultesi Hastanesi
Istanbul, 34093, Turkey (Türkiye)
-
MD Anderson Cancer Center
Madrid, 28015, Spain
-
Mfsmc-Hjwci
Baltimore, Maryland, 21237, United States
-
Nograd Varmegyei Szent Lazar Korhaz
Salgótarján, Nógrád megye, 3100, Hungary
-
Oaxaca Site Management Organization S.C.
Oaxaca City, 68000, Mexico
-
Ocala Oncology Center PL DBA Florida Cancer Affiliates
Ocala, Florida, 34474, United States
-
Parc de Salut Mar - Hospital del Mar
Barcelona, 08003, Spain
-
Renati Innovation S.A.P.I de C.V
Guadalajara, Jalisco, 44680, Mexico
-
Saint Luke's Cancer Institute
Kansas City, Missouri, 64111, United States
-
Semmelweis Egyetem
Budapest, 1082, Hungary
-
Sidney Kimmel Cancer Center - Jefferson Health
Philadelphia, Pennsylvania, 19107, United States
-
Soltmed SMO
Mexico City, Mexico City, 03650, Mexico
-
Szent Borbala Korhaz
Tatabánya, Komárom-Esztergom, 2800, Hungary
-
TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi
Istanbul, 34722, Turkey (Türkiye)
-
The Center for Cancer and Blood Disorders
Fort Worth, Texas, 76104, United States
-
Trakya University
Edirne, 22030, Turkey (Türkiye)
Conditions
Explore the condition pages connected to this study.